Keratoprosthesis prophylaxis: is it time for a paradigm shift?

JS Pelletier,1–3 SB Barone,1 JA Capriotii1,2 1Department of Ophthalmology, Veloce BioPharma LLC, Fort Lauderdale, FL, USA; 2Department of Ophthalmology, Plessen Ophthalmology Consultants, Christiansted, VI, USA; 3Department of Ophthalmology, Ocean Ophthalmology Group, Miami, FL, USA Abst...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pelletier JS, Barone SB, Capriotti JA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Keratoprosthesis ocular surface povidone-iodine antimicrobial resistance Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b051d6c841ca4371a752fdfcb6fbbc4f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b051d6c841ca4371a752fdfcb6fbbc4f
record_format	dspace
spelling	oai:doaj.org-article:b051d6c841ca4371a752fdfcb6fbbc4f2021-12-02T00:35:46ZKeratoprosthesis prophylaxis: is it time for a paradigm shift?1177-5483https://doaj.org/article/b051d6c841ca4371a752fdfcb6fbbc4f2018-09-01T00:00:00Zhttps://www.dovepress.com/keratoprosthesis-prophylaxis-is-it-time-for-a-paradigm-shift-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483JS Pelletier,1–3 SB Barone,1 JA Capriotii1,2 1Department of Ophthalmology, Veloce BioPharma LLC, Fort Lauderdale, FL, USA; 2Department of Ophthalmology, Plessen Ophthalmology Consultants, Christiansted, VI, USA; 3Department of Ophthalmology, Ocean Ophthalmology Group, Miami, FL, USA Abstract: The Boston Type I Keratoprosthesis has been improving in both design and safety since its inception. Due to particular features inherent in the Boston Type I Keratoprosthesis eye and certain aspects of the ocular surface, special attention is required to maintain these implanted devices. There is currently a prominent role for keratoprosthesis prophylaxis; it is designed to prevent infectious complications like keratitis and endophthalmitis. This standard-of-care therapy has anecdotally been shown to improve outcomes; however, it has not been examined in the setting of controlled clinical trials. Moreover, concerns remain with the chronic utilization of topical antibiotics in that they may engender antibiotic resistance and select for opportunistic populations to establish a foothold on the ocular surface. We believe and introduce the idea that there is merit in exploring other compounds besides antibiotics for prophylaxis such as antiseptics like povidone-iodine. Specifically developed formulations of povidone-iodine may prove useful in both improving keratoprosthesis safety and simultaneously mitigating concerns regarding antibiotic resistance. Keywords: keratoprosthesis, ocular surface, povidone-iodine, antimicrobial resistancePelletier JSBarone SBCapriotti JADove Medical PressarticleKeratoprosthesisocular surfacepovidone-iodineantimicrobial resistanceOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1785-1788 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Keratoprosthesis ocular surface povidone-iodine antimicrobial resistance Ophthalmology RE1-994
spellingShingle	Keratoprosthesis ocular surface povidone-iodine antimicrobial resistance Ophthalmology RE1-994 Pelletier JS Barone SB Capriotti JA Keratoprosthesis prophylaxis: is it time for a paradigm shift?
description	JS Pelletier,1–3 SB Barone,1 JA Capriotii1,2 1Department of Ophthalmology, Veloce BioPharma LLC, Fort Lauderdale, FL, USA; 2Department of Ophthalmology, Plessen Ophthalmology Consultants, Christiansted, VI, USA; 3Department of Ophthalmology, Ocean Ophthalmology Group, Miami, FL, USA Abstract: The Boston Type I Keratoprosthesis has been improving in both design and safety since its inception. Due to particular features inherent in the Boston Type I Keratoprosthesis eye and certain aspects of the ocular surface, special attention is required to maintain these implanted devices. There is currently a prominent role for keratoprosthesis prophylaxis; it is designed to prevent infectious complications like keratitis and endophthalmitis. This standard-of-care therapy has anecdotally been shown to improve outcomes; however, it has not been examined in the setting of controlled clinical trials. Moreover, concerns remain with the chronic utilization of topical antibiotics in that they may engender antibiotic resistance and select for opportunistic populations to establish a foothold on the ocular surface. We believe and introduce the idea that there is merit in exploring other compounds besides antibiotics for prophylaxis such as antiseptics like povidone-iodine. Specifically developed formulations of povidone-iodine may prove useful in both improving keratoprosthesis safety and simultaneously mitigating concerns regarding antibiotic resistance. Keywords: keratoprosthesis, ocular surface, povidone-iodine, antimicrobial resistance
format	article
author	Pelletier JS Barone SB Capriotti JA
author_facet	Pelletier JS Barone SB Capriotti JA
author_sort	Pelletier JS
title	Keratoprosthesis prophylaxis: is it time for a paradigm shift?
title_short	Keratoprosthesis prophylaxis: is it time for a paradigm shift?
title_full	Keratoprosthesis prophylaxis: is it time for a paradigm shift?
title_fullStr	Keratoprosthesis prophylaxis: is it time for a paradigm shift?
title_full_unstemmed	Keratoprosthesis prophylaxis: is it time for a paradigm shift?
title_sort	keratoprosthesis prophylaxis: is it time for a paradigm shift?
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b051d6c841ca4371a752fdfcb6fbbc4f
work_keys_str_mv	AT pelletierjs keratoprosthesisprophylaxisisittimeforaparadigmshift AT baronesb keratoprosthesisprophylaxisisittimeforaparadigmshift AT capriottija keratoprosthesisprophylaxisisittimeforaparadigmshift
_version_	1718403640468701184

Keratoprosthesis prophylaxis: is it time for a paradigm shift?

Ejemplares similares